Disease · MONDO_0003059
bile duct cancer
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. bile duct cancer. Diseases, record MONDO_0003059. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003059
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- cancer of bile duct, malignant bile duct neoplasm, malignant neoplasm of bile duct
- Open Targets
Drugs28
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| LEUCOVORIN | CHEMBL1679 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| MITAZALIMAB | CHEMBL4297870 | Antibody | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OXALIPLATIN | CHEMBL414804 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BECATECARIN | CHEMBL2107313 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOLASTATIN-10 | CHEMBL39541 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOSTARLIMAB | CHEMBL4298124 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 28
See all 28 drugsTargets59
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5604 | Drugs and targets |
| MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 2 | 2 | Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | Phase 2 | https://conductscience.org/library/genes/5605 | Drugs and targets |
| RRM1 | Ribonucleoside-diphosphate reductase RR1 | 2 | Ribonucleoside-diphosphate reductase RR1 inhibitor | Phase 2 | https://conductscience.org/library/genes/6240 | Drugs and targets |
| RRM2 | Ribonucleoside-diphosphate reductase RR1 | 2 | Ribonucleoside-diphosphate reductase RR1 inhibitor | Phase 2 | https://conductscience.org/library/genes/6241 | Drugs and targets |
| RRM2B | Ribonucleoside-diphosphate reductase RR1 | 2 | Ribonucleoside-diphosphate reductase RR1 inhibitor | Phase 2 | https://conductscience.org/library/genes/50484 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 2 | DNA topoisomerase I inhibitor | Phase 2 | https://conductscience.org/library/genes/7150 | Drugs and targets |
| TOP2A | DNA topoisomerase 2-alpha | 2 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 2 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| TYMS | Thymidylate synthase | 2 | Thymidylate synthase inhibitor | Phase 2/3 | https://conductscience.org/library/genes/7298 | Drugs and targets |
| AKT1 | Serine/threonine-protein kinase AKT | 1 | Serine/threonine-protein kinase AKT inhibitor | Phase 2 | https://conductscience.org/library/genes/207 | Drugs and targets |
| AKT2 | Serine/threonine-protein kinase AKT | 1 | Serine/threonine-protein kinase AKT inhibitor | Phase 2 | https://conductscience.org/library/genes/208 | Drugs and targets |
1 to 10 of 59
See all 59 targetsTrials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01828034 | First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma | Phase 1/2 | 42 | 2020-11-17 | Advanced Biliary Tract Carcinoma | BINIMETINIB, CISPLATIN, GEMCITABINE | Its record names the disease | ClinicalTrials.gov |
| NCT00919061 | Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy | Phase 2 | 39 | 2016-02-03 | Extrahepatic Bile Duct Cancer, Gallbladder Cancer | CISPLATIN, GEMCITABINE, SORAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT00478140 | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery | Phase 2 | 4 | 2013-11-19 | Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Malignant Neoplasm, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer | TRASTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02961101 | Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies | Phase 1/2 | 250 | Malignancies Multiple | DECITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07437287 | Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers | Phase 2/3 | 160 | Biliary Tract Cancer (BTC) | MITAZALIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT03964233 | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) | Phase 1 | 119 | Neoplasms | BRIGIMADLIN, EZABENLIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01317069 | A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer | Phase 2 | 100 | Gallbladder Cancer, Bile Duct Cancer | FLUOROURACIL | Its record names the disease | ClinicalTrials.gov | |
| NCT00005997 | Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer | Phase 2 | 72 | Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer | BECATECARIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab | Phase 2 | 51 | Urothelial Bladder Cancer, Gastric Adenocarcinoma, Gastro-oesophageal Adenocarcinoma, Head and Neck Cancer, Biliary Tract Cancer, Platinum-sensitive Urothelial Bladder Cancer, Clear Cell Renal Cell Carcinoma, Pancreatic Ductal Adenocarcinoma | DOSTARLIMAB, NIRAPARIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00073905 | Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer | Phase 2 | 44 | Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pain | CAPECITABINE, GEMCITABINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials9
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0003059
GET https://conductscience.org/api/diseases/v1/MONDO_0003059/drugs?page=2